October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, announced presentations on Axumin (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, to be held in Chicago, Ill., from October 24 to 27, 2021. Details of selected oral and moderated poster presentations are listed below.
NOTE: Axumin (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations noted by “*” discuss results of investigational studies of an approved product that is not approved by the FDA for the specific use or purpose noted.
|
HIGHLIGHTED SCIENTIFIC PRESENTATIONS |
||
|
Monday, October 25, 2021 |
||
|
Axumin (fluciclovine F 18) presentations |
||
|
Category: |
Genitourinary Cancer |
|
|
Title: |
Detectability Rates and Impact on Management From High-Sensitivity Total-Body 18F-Fluciclovine PET/CT Scans in Patients With Prostate Cancer Biochemical Recurrence |
|
|
Presenter: |
Soheila Fayeghi Azghadi, MD, Department of Radiation Oncology, Comprehensive Cancer Center, University of California Davis, Sacramento, Calif. |
|
|
Session Title: |
Poster Q&A 05 - Session 05 – Genitourinary Cancer, Hematology Malignancies, and Sarcoma and Cutaneous Tumors |
|
|
Presentation Time: |
1:30 PM CT |
|
|
Location: |
McCormick Place West, Outside Room W375 |
|
|
Presentation No.: |
2532 |
|
|
|
|
|
|
Category: |
Genitourinary Cancer |
|
|
Title: |
Randomized Trial of Conventional vs Conventional plus Fluciclovine (18F) PET/CT-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer: Volumetric and Patient-Reported Toxicity Analyses |
|
|
Presenter: |
Vishal Ramesh Dhere, MD, Winship Cancer Institute, Department of Radiation Oncology, Emory University, Atlanta, Ga. |
|
|
Session Title: |
Poster Q&A 05 - Session 05 – Genitourinary Cancer, Hematology Malignancies, and Sarcoma and Cutaneous Tumors |
|
|
Presentation Time: |
1:30 PM CT |
|
|
Location: |
McCormick Place West, Outside Room W375 |
|
|
Presentation No.: |
2547 |
|
|
|
|
|
|
Investigational 18F-fluciclovine presentation |
||
|
|
|
|
|
Category: |
Central Nervous System |
|
|
Session Title: |
18F-Fluciclovine PET/CT to Distinguish Radiation Necrosis From Tumor Progression in Brain Metastases Treated With Stereotactic Radiosurgery: Results of a Prospective Pilot Study* |
|
|
Presenter: |
Martin C. Tom, MD, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio |
|
|
Session Title: |
51 Oral presentation |
|
|
Presentation Time: |
12:15 PM CT |
|
|
Location: |
McCormick Place West, Room W194 a/b |
|
|
Presentation No.: |
51 |
|
Blue Earth Diagnostics invites participants at the 2021 ASTRO Annual Meeting to attend the presentations above and visit the company at Exhibit Booth 665. Blue Earth Diagnostics is hosting an Industry-Expert Theater event, “The Role of PET in Post-Prostatectomy Radiotherapy,” with invited speaker Dr. Ashesh Jani, MD, MSEE, FASTRO, James C. Kennedy Professor, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga. The event will be held on Sunday, October 24, 2021, from 12:30 to 1:30 PM CT, in Theater 1, Exhibition Floor. For full session details and scientific presentation listings, please see the ASTRO online program here.
July 30, 2024 
